VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q90174035 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235818.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q90174035‏
024 ‎‡a 0000-0003-2040-4961‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q90174035‏
100 0 ‎‡a Jennifer R Brown‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Jennifer R Brown‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay‏
670 ‎‡a Author's Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect‏
670 ‎‡a Author's DUO delivers for duvelisib‏
670 ‎‡a Author's Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia‏
670 ‎‡a Author's Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis‏
670 ‎‡a Author's MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL‏
670 ‎‡a Author's Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib‏
909 ‎‡a (orcid) 0000000320404961‏ ‎‡9 1‏
919 ‎‡a myd88l265pmutationsidentifyaprognosticgeneexpressionsignatureandapathwayfortargetedinhibitionincll‏ ‎‡A MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL‏ ‎‡9 1‏
919 ‎‡a riskfactorsforgrade34transaminaseelevationinpatientswithchroniclymphocyticleukemiatreatedwithidelalisib‏ ‎‡A Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib‏ ‎‡9 1‏
919 ‎‡a incidenceofandriskfactorsformajorhaemorrhageinpatientstreatedwithibrutinibanintegratedanalysis‏ ‎‡A Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis‏ ‎‡9 1‏
919 ‎‡a efficacyresultsofaphase2trialof1lineidelalisibplusofatumumabinchroniclymphocyticleukemia‏ ‎‡A Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia‏ ‎‡9 1‏
919 ‎‡a duodeliversforduvelisib‏ ‎‡A DUO delivers for duvelisib‏ ‎‡9 1‏
919 ‎‡a distinctevolutionarypathsinchroniclymphocyticleukemiaduringresistancetothegraftversusleukemiaeffect‏ ‎‡A Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect‏ ‎‡9 1‏
919 ‎‡a prospectivestudyofminimalresidualdiseaseinpatientswithdiffuselargebcelllymphomausinganigngsassay‏ ‎‡A A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 LC|n 2023035420
996 ‎‡2 SUDOC|201776804
996 ‎‡2 NTA|086967584
996 ‎‡2 SUDOC|263917940
996 ‎‡2 NUKAT|n 2010132555
996 ‎‡2 DNB|1174691417
996 ‎‡2 SUDOC|251367800
996 ‎‡2 CAOONL|ncf13693618
996 ‎‡2 NKC|jo2014839069
996 ‎‡2 DNB|171369564
996 ‎‡2 JPG|500028267
996 ‎‡2 LC|nr 94031574
996 ‎‡2 B2Q|0000274291
996 ‎‡2 DNB|1043544038
996 ‎‡2 LC|n 83009859
996 ‎‡2 ISNI|0000000446171227
996 ‎‡2 RERO|A025437109
996 ‎‡2 ISNI|0000000051641175
996 ‎‡2 NUKAT|n 2017182343
996 ‎‡2 BNF|12340883
996 ‎‡2 NTA|072385944
996 ‎‡2 DNB|134915658
996 ‎‡2 J9U|987007281191205171
996 ‎‡2 BIBSYS|98061006
996 ‎‡2 LC|n 2014053884
996 ‎‡2 PLWABN|9813703869005606
996 ‎‡2 CAOONL|ncf10534031
996 ‎‡2 SUDOC|032365136
996 ‎‡2 LC|n 00039326
996 ‎‡2 NTA|11030490X
996 ‎‡2 BIBSYS|10011243
996 ‎‡2 LC|no2003086959
996 ‎‡2 NSK|000326304
996 ‎‡2 RERO|A012621998
996 ‎‡2 BNF|14024343
996 ‎‡2 BLBNB|001009360
996 ‎‡2 N6I|vtls000031252
996 ‎‡2 BNF|14024345
996 ‎‡2 LC|n 2019042669
996 ‎‡2 SIMACOB|23464035
996 ‎‡2 LC|n 2019020294
996 ‎‡2 LC|nb2013005806
996 ‎‡2 SUDOC|255245289
996 ‎‡2 LC|n 85244498
996 ‎‡2 DNB|1029522863
996 ‎‡2 SUDOC|151318018
996 ‎‡2 DNB|171992024
996 ‎‡2 LC|no2010091928
996 ‎‡2 LC|no 98083068
996 ‎‡2 BIBSYS|8007463
996 ‎‡2 SUDOC|242737900
996 ‎‡2 ISNI|0000000495494663
996 ‎‡2 DNB|1152408364
996 ‎‡2 ISNI|0000000433612732
996 ‎‡2 BIBSYS|90181220
996 ‎‡2 ISNI|0000000384971666
996 ‎‡2 NKC|jo2013779499
996 ‎‡2 LC|n 92105961
996 ‎‡2 NKC|jo2016917241
996 ‎‡2 ISNI|000000042563822X
996 ‎‡2 ISNI|0000000019894498
996 ‎‡2 LC|no2011158769
996 ‎‡2 BNF|18050758
996 ‎‡2 NKC|ola2017960354
996 ‎‡2 ISNI|0000000109067250
996 ‎‡2 RERO|A026884896
996 ‎‡2 ISNI|0000000368743735
996 ‎‡2 CAOONL|ncf10103517
996 ‎‡2 RERO|A013168260
996 ‎‡2 NUKAT|n 2011045948
996 ‎‡2 LC|nb 99082740
996 ‎‡2 LC|no2001080580
996 ‎‡2 NTA|391735993
996 ‎‡2 DNB|1033788228
996 ‎‡2 NKC|xx0228647
996 ‎‡2 ISNI|0000000051729644
996 ‎‡2 SUDOC|188917225
996 ‎‡2 J9U|987007576117205171
996 ‎‡2 N6I|vtls002070249
996 ‎‡2 LC|nr 91006185
996 ‎‡2 LC|nb2021001428
996 ‎‡2 NKC|xx0004119
996 ‎‡2 CAOONL|ncf11397458
996 ‎‡2 J9U|987007371606605171
996 ‎‡2 CAOONL|ncf11403668
996 ‎‡2 PTBNP|257610
996 ‎‡2 LC|n 2004063205
996 ‎‡2 ISNI|0000000451357552
996 ‎‡2 LC|nr 92021696
996 ‎‡2 ISNI|0000000049751893
996 ‎‡2 CAOONL|ncf10179506
996 ‎‡2 SUDOC|071284729
996 ‎‡2 BIBSYS|90659066
996 ‎‡2 RERO|A003048224
996 ‎‡2 RERO|A003048225
996 ‎‡2 NTA|069610339
996 ‎‡2 LC|n 2022938523
996 ‎‡2 N6I|vtls002421331
996 ‎‡2 CAOONL|ncf10807652
996 ‎‡2 BIBSYS|90220540
996 ‎‡2 J9U|987007371623005171
996 ‎‡2 ISNI|0000000390512829
996 ‎‡2 J9U|987007426998205171
996 ‎‡2 NSK|000259281
996 ‎‡2 RERO|A006372218
996 ‎‡2 RERO|A006372219
996 ‎‡2 ISNI|0000000021618927
996 ‎‡2 BIBSYS|90096526
996 ‎‡2 RERO|A006372216
996 ‎‡2 LC|n 2008079573
996 ‎‡2 CAOONL|ncf10380355
996 ‎‡2 DNB|172005515
996 ‎‡2 NTA|153676124
996 ‎‡2 ISNI|0000000082391025
996 ‎‡2 LC|no2005068756
996 ‎‡2 BIBSYS|90068577
996 ‎‡2 B2Q|0000011421
996 ‎‡2 NII|DA10890298
996 ‎‡2 DNB|14312854X
996 ‎‡2 NII|DA05153406
996 ‎‡2 LC|no2021109466
996 ‎‡2 LC|nb2021000738
996 ‎‡2 ISNI|0000000112828399
996 ‎‡2 LC|no2005020163
996 ‎‡2 SUDOC|112174663
996 ‎‡2 NTA|097313246
996 ‎‡2 BIBSYS|90138480
996 ‎‡2 PTBNP|1196483
996 ‎‡2 DNB|1251512798
996 ‎‡2 LC|no2005100997
996 ‎‡2 BIBSYS|99022480
996 ‎‡2 NUKAT|n 2006109309
996 ‎‡2 LC|n 2010060537
996 ‎‡2 NYNYRILM|39394
996 ‎‡2 ISNI|0000000109358197
996 ‎‡2 ISNI|0000000076642780
996 ‎‡2 ISNI|0000000050443134
996 ‎‡2 J9U|987010188922005171
996 ‎‡2 NUKAT|n 2017159667
996 ‎‡2 NTA|072856823
996 ‎‡2 LC|no2024078049
996 ‎‡2 DBC|87097990308564
996 ‎‡2 RERO|A003048265
996 ‎‡2 RERO|A003048266
996 ‎‡2 RERO|A003048267
996 ‎‡2 JPG|500068740
996 ‎‡2 ISNI|000000004824104X
996 ‎‡2 RERO|A003048268
996 ‎‡2 ISNI|000000047240790X
996 ‎‡2 ISNI|0000000025263000
996 ‎‡2 NTA|344497615
996 ‎‡2 ISNI|0000000114642408
996 ‎‡2 BNF|12021702
996 ‎‡2 NTA|433000325
996 ‎‡2 LC|no2016142871
996 ‎‡2 NTA|331239760
996 ‎‡2 ISNI|0000000457896514
996 ‎‡2 BIBSYS|90147677
996 ‎‡2 J9U|987007400624405171
996 ‎‡2 LC|n 80153184
996 ‎‡2 LC|n 2015072487
996 ‎‡2 BNC|981058616161106706
996 ‎‡2 ISNI|0000000496486841
996 ‎‡2 CAOONL|ncf10137406
996 ‎‡2 CAOONL|ncf10374879
996 ‎‡2 DNB|1212802314
996 ‎‡2 LC|n 97103554
996 ‎‡2 CAOONL|ncf11964157
996 ‎‡2 LC|no 90015316
996 ‎‡2 VLACC|000039187
996 ‎‡2 ISNI|0000000507733087
996 ‎‡2 LC|no2024044036
996 ‎‡2 ISNI|0000000357602056
996 ‎‡2 DNB|1156970679
996 ‎‡2 NTA|167561820
996 ‎‡2 DNB|1318496853
996 ‎‡2 LC|no2021091320
996 ‎‡2 BIBSYS|13046396
996 ‎‡2 DNB|103760394X
996 ‎‡2 LC|n 2017065461
996 ‎‡2 LC|n 2017065463
996 ‎‡2 J9U|987007361118705171
996 ‎‡2 BAV|495_388251
996 ‎‡2 LC|n 2003016211
996 ‎‡2 BNF|16189122
996 ‎‡2 CAOONL|ncf10039400
996 ‎‡2 CAOONL|ncf12094826
996 ‎‡2 NUKAT|n 2014082338
996 ‎‡2 SUDOC|05971574X
996 ‎‡2 LC|no2013057121
996 ‎‡2 LC|n 2019022126
996 ‎‡2 J9U|987007425325505171
996 ‎‡2 BNF|16736780
996 ‎‡2 DNB|1052879551
996 ‎‡2 BIBSYS|10027522
996 ‎‡2 LC|n 85339763
996 ‎‡2 ISNI|000000044884750X
996 ‎‡2 PLWABN|9810644198905606
996 ‎‡2 PTBNP|1003533
996 ‎‡2 J9U|987012747986705171
996 ‎‡2 DNB|1062526392
996 ‎‡2 NUKAT|n 2021025444
996 ‎‡2 CAOONL|ncf10617277
996 ‎‡2 ISNI|0000000034224222
996 ‎‡2 LC|n 2019060828
996 ‎‡2 LC|n 2013057548
996 ‎‡2 CAOONL|ncf10731954
996 ‎‡2 SUDOC|233054588
996 ‎‡2 ISNI|0000000024510495
996 ‎‡2 CAOONL|ncf11546106
996 ‎‡2 BIBSYS|90264731
996 ‎‡2 LC|nb2020008542
996 ‎‡2 BIBSYS|90114367
996 ‎‡2 SUDOC|183927044
996 ‎‡2 LC|n 2012032479
996 ‎‡2 CAOONL|ncf10036893
996 ‎‡2 DNB|117113990X
996 ‎‡2 PLWABN|9810642867005606
996 ‎‡2 B2Q|0001644302
996 ‎‡2 N6I|vtls000043780
996 ‎‡2 UIY|000084780
996 ‎‡2 J9U|987007351720505171
996 ‎‡2 LC|n 2019040496
996 ‎‡2 DNB|1201595622
996 ‎‡2 LC|no2021068515
996 ‎‡2 NTA|071027335
996 ‎‡2 ISNI|0000000399440286
996 ‎‡2 ISNI|0000000044757903
996 ‎‡2 LC|no2002109403
996 ‎‡2 LC|no2015163382
996 ‎‡2 BNF|16200631
996 ‎‡2 NTA|089188241
996 ‎‡2 DNB|141890762
996 ‎‡2 RERO|A027683211
996 ‎‡2 N6I|vtls002658312
996 ‎‡2 ISNI|0000000050292903
996 ‎‡2 ISNI|0000000080565458
996 ‎‡2 ISNI|0000000076332109
996 ‎‡2 NKC|ola2006329805
996 ‎‡2 LC|no2014147882
996 ‎‡2 ISNI|0000000495871406
996 ‎‡2 SZ|1251512798
996 ‎‡2 ISNI|0000000036809339
996 ‎‡2 B2Q|0000099476
996 ‎‡2 BIBSYS|90231650
996 ‎‡2 J9U|987007460360905171
996 ‎‡2 LC|no2020025593
996 ‎‡2 ISNI|0000000036678607
996 ‎‡2 CAOONL|ncf11865420
996 ‎‡2 LC|n 93115837
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Brown, Jennifer R.‏ ‎‡2 J9U|987007350340605171‏ ‎‡3 viafid‏ ‎‡3 title: (0.70, 'chroniclymphocyticleukemia', 'efficacyresultsofaphase2trialof1lineidelalisibplusofatumumabinchroniclymphocyticleukemia')‏
998 ‎‡a Brown, Jennifer R.‏ ‎‡2 NKC|xx0173543‏ ‎‡3 title: (0.70, 'chroniclymphocyticleukemia', 'efficacyresultsofaphase2trialof1lineidelalisibplusofatumumabinchroniclymphocyticleukemia')‏
998 ‎‡a Brown, Jennifer R.‏ ‎‡2 LC|nb2013010028‏ ‎‡3 title: (0.70, 'chroniclymphocyticleukemia', 'efficacyresultsofaphase2trialof1lineidelalisibplusofatumumabinchroniclymphocyticleukemia')‏